Feasibility of detecting prostate cancer by ultraperformance liquid chromatography-mass spectrometry serum metabolomics

Journal of Proteome Research

Volumn 13, Issue 7, 2014, Pages 3444-3454

  Zang, Xiaoling ^a   Jones, Christina M ^a   Long, Tran Q ^a   Monge, María Eugenia ^a,c   Zhou, Manshui ^a   Walker, L Deette ^b   Mezencev, Roman ^b   Gray, Alexander ^a   McDonald, John F ^b   Fernández, Facundo M ^a,b  

^a School of Chemistry and Biochemistry   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^c Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

Author keywords

in vitro diagnostic multivariate index assay; IVDMIA; machine learning methods; mass spectrometry; oncometabolomics; prostate cancer; prostate cancer detection; support vector machines; ultraperformance liquid chromatography; untargeted metabolomics

Indexed keywords

AMINO ACID; BILE ACID; FATTY ACID; LYSOPHOSPHOLIPID; PROSTATE SPECIFIC ANTIGEN; STEROID HORMONE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; HUMAN; IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAY; IN VITRO STUDY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; METABOLITE; METABOLOMICS; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER PROGNOSTIC TEST; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; STEROIDOGENESIS; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CASE CONTROL STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOLATION AND PURIFICATION; MIDDLE AGED; PROSTATIC NEOPLASMS;

AGED; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEASIBILITY STUDIES; HUMANS; MALE; METABOLOMICS; MIDDLE AGED; PROSTATIC NEOPLASMS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84903698018     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr500409q     Document Type: Article

References (78)

1. Cancer Facts & Figures 2013; American Cancer Society, Atlanta, GA, 2013.
2. Cancer Facts & Figures 2010; American Cancer Society, Atlanta, GA, 2010.
3. Nadler, R. B.; Humphrey, P. A.; Smith, D. S.; Catalona, W. J.; Ratliff, T. L. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate-specific antigen levels J. Urol. 1995, 154 (2) 407-413
4. Tombal, B. Over- and underdiagnosis of prostate cancer: the dangers Eur. Urol. Suppl. 2006, 5 (6) 511-513
5. Bickers, B.; Aukim-Hastie, C. New molecular biomarkers for the prognosis and management of prostate cancer-the post PSA era Anticancer Res. 2009, 29 (8) 3289-3298
6. Heijnsdijk, E. A. M.; der Kinderen, A.; Wever, E. M.; Draisma, G.; Roobol, M. J.; de Koning, H. J. Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br. J. Cancer 2009, 101 (11) 1833-1838
7. Draisma, G.; Etzioni, R.; Tsodikov, A.; Mariotto, A.; Wever, E.; Gulati, R.; Feuer, E.; de Koning, H. Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context J. Natl. Cancer Inst. 2009, 101 (6) 374-383
8. Trock, B. J. Application of metabolomics to prostate cancer Urol. Oncol.: Semin. Orig. Invest. 2011, 29 (5) 572-581
9. Chace, D. H.; Kalas, T. A.; Naylor, E. W. The application of tandem mass spectrometry to neonatal screening for inherited disorders of intermediary metabolism Annu. Rev. Genomics Hum. Genet. 2002, 3, 17-45
10. Piraud, M.; Vianey-Saban, C.; Petritis, K.; Elfakir, C.; Steghens, J. P.; Morla, A.; Bouchu, D. ESI-MS/MS analysis of underivatised amino acids: a new tool for the diagnosis of inherited disorders of amino acid metabolism. Fragmentation study of 79 molecules of biological interest in positive and negative ionisation mode Rapid Commun. Mass Spectrom. 2003, 17 (12) 1297-1311
11. Sreekumar, A.; Poisson, L. M.; Rajendiran, T. M.; Khan, A. P.; Cao, Q.; Yu, J. D.; Laxman, B.; Mehra, R.; Lonigro, R. J.; Li, Y.; Nyati, M. K.; Ahsan, A.; Kalyana-Sundaram, S.; Han, B.; Cao, X. H.; Byun, J.; Omenn, G. S.; Ghosh, D.; Pennathur, S.; Alexander, D. C.; Berger, A.; Shuster, J. R.; Wei, J. T.; Varambally, S.; Beecher, C.; Chinnaiyan, A. M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 2009, 457 (7231) 910-914
12. Jentzmik, F.; Stephan, C.; Miller, K.; Schrader, M.; Erbersdobler, A.; Kristiansen, G.; Lein, M.; Jung, K. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours Eur. Urol. 2010, 58 (1) 12-18
13. Schalken, J. A. Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development Eur. Urol. 2010, 58 (1) 19-20
14. Struys, E. A.; Heijboer, A. C.; van Moorselaar, J.; Jakobs, C.; Blankenstein, M. A. Serum sarcosine is not a marker for prostate cancer Ann. Clin. Biochem. 2010, 47, 282-282
15. Swanson, M. G.; Vigneron, D. B.; Tabatabai, Z. L.; Males, R. G.; Schmitt, L.; Carroll, P. R.; James, J. K.; Hurd, R. E.; Kurhanewicz, J. Proton HR-MAS spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI-targeted postsurgical prostate tissues Magn. Reson. Med. 2003, 50 (5) 944-954
16. Swanson, M. G.; Zektzer, A. S.; Tabatabai, Z. L.; Simko, J.; Jarso, S.; Keshari, K. R.; Schmitt, L.; Carroll, P. R.; Shinohara, K.; Vigneron, D. B.; Kurhanewicz, J. Quantitative analysis of prostate metabolites using H-1 HR-MAS spectroscopy Magn. Reson. Med. 2006, 55 (6) 1257-1264
17. Thysell, E.; Surowiec, I.; Hornberg, E.; Crnalic, S.; Widmark, A.; Johansson, A. I.; Stattin, P.; Bergh, A.; Moritz, T.; Antti, H.; Wikstro, P. Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol PLoS One 2010, 5 (12) e14175
18. Zhou, X. C.; Mao, J. H.; Ai, J. M.; Deng, Y. P.; Roth, M. R.; Pound, C.; Henegar, J.; Welti, R.; Bigler, S. A. Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics PLoS One 2012, 7 (11) e48889
19. Boccard, J.; Veuthey, J. L.; Rudaz, S. Knowledge discovery in metabolomics: an overview of MS data handling J. Sep. Sci. 2010, 33 (3) 290-304
20. Eliasson, M.; Rannar, S.; Trygg, J. From data processing to multivariate validation-essential steps in extracting interpretable information from metabolomics data Curr. Pharm. Biotechnol. 2011, 12 (7) 996-1004
21. Madsen, R.; Lundstedt, T.; Trygg, J. Chemometrics in metabolomics-a review in human disease diagnosis Anal. Chim. Acta 2010, 659 (1-2) 23-33
22. Guan, W.; Zhou, M.; Hampton, C.; Benigno, B.; Walker, L. D.; Gray, A.; McDonald, J.; Fernandez, F. Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines BMC Bioinf. 2009, 10 (1) 259
23. Zhou, M. S.; Guan, W.; Walker, L. D.; Mezencev, R.; Benigno, B. B.; Gray, A.; Fernandez, F. M.; McDonald, J. F. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy Cancer Epidemiol., Biomarkers Prev. 2010, 19 (9) 2262-2271
24. Lokhov, P. G.; Kharybin, O. N.; Archakov, A. I. Diagnosis of lung cancer based on direct-infusion electrospray mass spectrometry of blood plasma metabolites Int. J. Mass Spectrom. 2012, 309, 200-205
25. Frickenschmidt, A.; Frohlich, H.; Bullinger, D.; Zell, A.; Laufer, S.; Gleiter, C. H.; Liebich, H.; Kammerer, B. Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients Biomarkers 2008, 13 (4) 435-449
26. Zhang, Z. An in vitro diagnostic multivariate index assay (IVDMIA) for ovarian cancer: harvesting the power of multiple biomarkers Rev. Obstet. Gynecol. 2012, 5 (1) 35-41
27. Brereton, R. G.; Lloyd, G. R. Support vector machines for classification and regression Analyst 2010, 135 (2) 230-267
28. Smith, C. A.; OMaille, G.; Want, E. J.; Qin, C.; Trauger, S. A.; Brandon, T. R.; Custodio, D. E.; Abagyan, R.; Siuzdak, G. METLIN: a metabolite mass spectral database Ther. Drug Monit. 2005, 27 (6) 747-751
29. Wishart, D. S.; Jewison, T.; Guo, A. C.; Wilson, M.; Knox, C.; Liu, Y. F.; Djoumbou, Y.; Mandal, R.; Aziat, F.; Dong, E.; Bouatra, S.; Sinelnikov, I.; Arndt, D.; Xia, J. G.; Liu, P.; Yallou, F.; Bjorndahl, T.; Perez-Pineiro, R.; Eisner, R.; Allen, F.; Neveu, V.; Greiner, R.; Scalbert, A. HMDB 3.0: the human metabolome database in 2013 Nucleic Acids Res. 2013, 41 (D1) D801-D807
30. Horai, H.; Arita, M.; Kanaya, S.; Nihei, Y.; Ikeda, T.; Suwa, K.; Ojima, Y.; Tanaka, K.; Tanaka, S.; Aoshima, K.; Oda, Y.; Kakazu, Y.; Kusano, M.; Tohge, T.; Matsuda, F.; Sawada, Y.; Hirai, M. Y.; Nakanishi, H.; Ikeda, K.; Akimoto, N.; Maoka, T.; Takahashi, H.; Ara, T.; Sakurai, N.; Suzuki, H.; Shibata, D.; Neumann, S.; Iida, T.; Tanaka, K.; Funatsu, K.; Matsuura, F.; Soga, T.; Taguchi, R.; Saito, K.; Nishioka, T. MassBank: a public repository for sharing mass spectral data for life sciences J. Mass Spectrom. 2010, 45 (7) 703-714
31. Nicholson, J. K.; Lindon, J. C. Systems biology: metabonomics Nature 2008, 455 (7216) 1054-1056
32. Liu, Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer Prostate Cancer Prostatic Dis. 2006, 9 (3) 230-234
33. Ebenezar, J.; Pu, Y.; Wang, W. B.; Liu, C. H.; Alfano, R. R. Stokes shift spectroscopy pilot study for cancerous and normal prostate tissues Appl. Opt. 2012, 51 (16) 3642-3649
34. Fu, Y. M.; Lin, H.; Liu, X.; Fang, W.; Meadows, G. G. Cell death of prostate cancer cells by specific amino acid restriction depends on alterations of glucose metabolism J. Cell Physiol. 2010, 224 (2) 491-500
35. Peyruchaud, O. Novel implications for lysophospholipids, lysophosphatidic acid and sphingosine 1-phosphate, as drug targets in cancer Anti-Cancer Agents Med. Chem. 2009, 9 (4) 381-391
36. Brys, M.; Morel, A.; Forma, E.; Krzeslak, A.; Wilkosz, J.; Rozanski, W.; Olas, B. Relationship of urinary isoprostanes to prostate cancer occurence Mol. Cell. Biochem. 2013, 372 (1-2) 149-153
37. Fini, M.; Elias, A.; Johnson, R.; Wright, R. Contribution of uric acid to cancer risk, recurrence, and mortality Clin. Transl. Med. 2012, 1 (1) 16
38. Kolonel, L.; Yoshizawa, C.; Nomura, A.; Stemmermann, G. Relationship of serum uric acid to cancer occurrence in a prospective male cohort Cancer Epidemiol. Biomarkers Prev. 1994, 3 (3) 225-228
39. Tsimberidou, A.; Keating, M. Hyperuricemic syndromes in cancer patients Contrib. Nephrol. 2005, 147, 47-60
40. Barreto, F. C.; Barreto, D. V.; Liabeuf, S.; Meert, N.; Glorieux, G.; Temmar, M.; Choukroun, G.; Vanholder, R.; Massy, Z. A. European uremic toxin work grp, e.u.t., serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients Clin. J. Am. Soc. Nephrol. 2009, 4 (10) 1551-1558
41. Dou, L.; Jourde-Chiche, N.; Faure, V.; Cerini, C.; Berland, Y.; Dignat-George, F.; Brunet, P. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells J. Thromb. Haemost. 2007, 5 (6) 1302-1308
42. Kliman, B.; Prout, G. R.; Maclaughlin, R. A.; Daly, J. J.; Griffin, P. P. Altered androgen metabolism in metastatic prostate cancer J. Urol. 1978, 119 (5) 623-626
43. Titus, M. A.; Schell, M. J.; Lih, F. B.; Tomer, K. B.; Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer Clin. Cancer Res. 2005, 11 (13) 4653-4657
44. Zumoff, B.; Levin, J.; Strain, G. W.; Rosenfeld, R. S.; Oconnor, J.; Freed, S. Z.; Kream, J.; Whitmore, W. S.; Fukushima, D. K.; Hellman, L. Abnormal levels of plasma hormones in men with prostate-cancer: evidence toward a 2-disease theory Prostate 1982, 3 (6) 579-588
45. Knudsen, K. E.; Scher, H. I. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer Clin. Cancer Res. 2009, 15 (15) 4792-4798
46. Horton, R.; Frasier, S. D. Androstenedione and its conversion to plasma testosterone in congenital adrenal hyperplasia J. Clin. Invest. 1967, 46 (6) 1003
47. Speiser, P. W.; White, P. C. Congenital adrenal hyperplasia N. Engl. J. Med. 2003, 349 (8) 776-788
48. Passi, S.; Picardo, M.; De Luca, C.; Nazzaro-Porro, M. Mechanism of azelaic acid action in acne G. Ital. Dermatol. Venereol. 1989, 124 (10) 455-463
49. Breathnach, A. S. Azelaic acid: potential as a general antitumoural agent Med. Hypotheses 1999, 52 (3) 221-226
50. Dong, R. H.; Fang, Z. Z.; Zhu, L. L.; Ge, G. B.; Cao, Y. F.; Li, X. B.; Hu, C. M.; Yang, L.; Liu, Z. Y. Identification of CYP isoforms involved in the metabolism of thymol and carvacrol in human liver microsomes (HLMs) Pharmazie 2012, 67 (12) 1002-1006
51. Miyazawa, M.; Marumoto, S.; Takahashi, T.; Nakahashi, H.; Haigou, R.; Nakanishi, K. metabolism of (+)- and (-)-menthols by CYP2A6 in human liver microsomes J. Oleo Sci. 2011, 60 (3) 127-132
52. Anderton, M. J.; Manson, M. M.; Verschoyle, R. D.; Gescher, A.; Lamb, J. H.; Farmer, P. B.; Steward, W. P.; Williams, M. L. Pharmacokinetics and tissue disposition of indole-3-carbinol and its acid condensation products after oral administration to mice Clin. Cancer Res. 2004, 10 (15) 5233-5241
53. Souli, E.; Machluf, M.; Morgenstern, A.; Sabo, E.; Yannai, S. Indole-3-carbinol (I3C) exhibits inhibitory and preventive effects on prostate tumors in mice Food Chem. Toxicol. 2008, 46 (3) 863-870
54. Heinonen, O. P.; Albanes, D.; Virtamo, J.; Taylor, P. R.; Huttunen, J. K.; Hartman, A. M.; Haapakoski, J.; Malila, N.; Rautalahti, M.; Ripatti, S.; Maenpaa, H.; Teerenhovi, L.; Koss, L.; Virolainen, M.; Edwards, B. K. Prostate cancer and supplementation with ω-tocopherol and β-carotene: incidence and mortality in a controlled trial J. Natl. Cancer Inst. 1998, 90 (6) 440-446
55. Prendergast, G. C. Cancer: why tumours eat tryptophan Nature 2011, 478 (7368) 192-194
56. Crowe, F. L.; Allen, N. E.; Appleby, P. N.; Overvad, K.; Aardestrup, I. V.; Johnsen, N. F.; Tjonneland, A.; Linseisen, J.; Kaaks, R.; Boeing, H.; Kroger, J.; Trichopoulou, A.; Zavitsanou, A.; Trichopoulos, D.; Sacerdote, C.; Palli, D.; Tumino, R.; Agnoli, C.; Kiemeney, L. A.; Bueno-de-Mesquita, H. B.; Chirlaque, M. D.; Ardanaz, E.; Larranaga, N.; Quiros, J. R.; Sanchez, M. J.; Gonzalez, C. A.; Stattin, P.; Hallmans, G.; Bingham, S.; Khaw, K. T.; Rinaldi, S.; Slimani, N.; Jenab, M.; Riboli, E.; Key, T. J. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition Am. J. Clin. Nutr. 2008, 88 (5) 1353-1363
57. Glasgow, W.; Eling, T. Structural requirements for enhancement of EGF-dependent DNA synthesis by oxygenated metabolltes of linoleic acid. In Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation, and Radiation Injury 2; Honn, K.; Nigam, S.; Marnett, L., Eds.; Springer: New York, 1997; Vol. 400, pp 507-512.
58. Tserng, K. Y.; Jin, S. J. Metabolic origin of urinary 3-hydroxy dicarboxylic acids Biochemistry 1991, 30 (9) 2508-2514
59. Zha, S.; Ferdinandusse, S.; Hicks, J. L.; Denis, S.; Dunn, T. A.; Wanders, R. J.; Luo, J.; De Marzo, A. M.; Isaacs, W. B. Peroxisomal branched chain fatty acid β-oxidation pathway is upregulated in prostate cancer Prostate 2005, 63 (4) 316-323
60. Pettersson, A.; Kasperzyk, J. L.; Kenfield, S. A.; Richman, E. L.; Chan, J. M.; Willett, W. C.; Stampfer, M. J.; Mucci, L. A.; Giovannucci, E. L. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death Cancer Epidemiol., Biomarkers Prev. 2012, 21 (3) 428-436
61. Sun, H.; Zhang, A. H.; Yan, G. L.; Piao, C. Y.; Li, W. Y.; Sun, C.; Wu, X. H.; Li, X. H.; Chen, Y.; Wang, X. J. Metabolomic analysis of key regulatory metabolites in hepatitis C virus-infected tree shrews Mol. Cell. Proteomics 2013, 12 (3) 710-719
62. Cho, H. J.; Kim, J. D.; Lee, W. Y.; Chung, B. C.; Choi, M. H. Quantitative metabolic profiling of 21 endogenous corticosteroids in urine by liquid chromatography-triple quadrupole-mass spectrometry Anal. Chim. Acta 2009, 632 (1) 101-108
63. Schatzl, G.; Reiter, W. J.; Thurridl, T.; Waldmuller, J.; Roden, M.; Soregi, S.; Madersbacher, S. Endocrine patterns in patients with benign and malignant prostatic diseases Prostate 2000, 44 (3) 219-224
64. Barrett-Connor, E.; Garland, C.; McPhillips, J. B.; Khaw, K. T.; Wingard, D. L. A prospective, population-based study of androstenedione, estrogens, and prostatic cancer Cancer Res. 1990, 50 (1) 169-173
65. Li, Q.; Wang, X.; Yang, Z.; Wang, B.; Li, S. Menthol induces cell death via the TRPM8 channel in the human bladder cancer cell line T24 Oncology 2009, 77 (6) 335-341
66. Lin, J. P.; Lu, H. F.; Lee, J. H.; Lin, J. G.; Hsia, T. C.; Wu, L. T.; Chung, J. G. (-)-Menthol inhibits DNA topoisomerases I, II ω and β and promotes NF-κB expression in human gastric cancer SNU-5 cells Anticancer Res. 2005, 25 (3B) 2069-2074
67. Sacchetti, G.; Maietti, S.; Muzzoli, M.; Scaglianti, M.; Manfredini, S.; Radice, M.; Bruni, R. Comparative evaluation of 11 essential oils of different origin as functional antioxidants, antiradicals and antimicrobials in foods Food Chem. 2005, 91 (4) 621-632
68. Brito, R. G.; Guimaraes, A. G.; Quintans, J. S. S.; Santos, M. R. V.; De Sousa, D. P.; Badaue-Passos, D., Jr.; de Lucca, W., Jr.; Brito, F. A.; Barreto, E. O.; Oliveira, A. P.; Quintans, L. J., Jr. Citronellol, a monoterpene alcohol, reduces nociceptive and inflammatory activities in rodents J. Nat. Med. 2012, 66 (4) 637-644
69. Lau, A.; Villeneuve, N. F.; Sun, Z.; Wong, P. K.; Zhang, D. D. Dual roles of Nrf2 in cancer Pharmacol. Res. 2008, 58 (5-6) 262-270
70. Collett, G. P.; Betts, A. M.; Johnson, M. I.; Pulimood, A. B.; Cook, S.; Neal, D. E.; Robson, C. N. Peroxisome proliferator-activated receptor ω is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma Clin. Cancer Res. 2000, 6 (8) 3241-3248
71. Shearer, G. C.; Harris, W. S.; Pedersen, T. L.; Newman, J. W. Detection of omega-3 oxylipins in human plasma and response to treatment with omega-3 acid ethyl esters J. Lipid Res. 2010, 51 (8) 2074-2081
72. Karlaganis, G.; Bremmelgaard, A.; Karlaganis, V.; Sjovall, J. Precursor of 27-nor-5β-cholestane-3ω,7ω,12ω,24,25-pentol in man J. Steroid Biochem. Mol. Biol. 1983, 18 (6) 725-729
73. Krycer, J. R.; Brown, A. J. Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective Biochim. Biophys. Acta, Rev. Cancer 2013, 1835 (2) 219-229
74. Li, F.; Qin, X.; Chen, H.; Qiu, L.; Guo, Y.; Liu, H.; Chen, G.; Song, G.; Wang, X.; Li, F.; Guo, S.; Wang, B.; Li, Z. Lipid profiling for early diagnosis and progression of colorectal cancer using direct-infusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry Rapid Commun. Mass Spectrom. 2013, 27 (1) 24-34
75. Onishi, T.; Yamakawa, K.; Franco, O. E.; Suzuki, R.; Kawamura, J. p27(Kip1) is the key mediator of phenylacetate induced cell cycle arrest in human prostate cancer cells Anticancer Res. 2000, 20 (5A) 3075-3081
76. Shibahara, T.; Onishi, T.; Franco, O. E.; Arima, K.; Sugimura, Y. Down-regulation of Skp2 is correlated with p27-associated cell cycle arrest induced by phenylacetate in human prostate cancer cells Anticancer Res. 2005, 25 (3B) 1881-1888
77. Goldberg, A. A.; Titorenko, V. I.; Beach, A.; Sanderson, J. T. Bile acids induce apoptosis selectively in androgen-dependent and -independent prostate cancer cells PeerJ 2013, 1, e122
78. Patel, B.; Shah, V. R.; Bavadekar, S. A. Anti-proliferative effects of carvacrol on human prostate cancer cell line, LNCaP FASEB J. 2012, 26, 1037.5